The Global Dysphagia Management Market is estimated to be valued at US$ 4.4 billion in 2023 and is expected to exhibit a CAGR of 6.2% during the forecast period (2023-2030).
Analysts’ Views on Global Dysphagia Management Market:
According to the definition of dysphagia, it is an actual impairment or difficulty swallowing that causes an unnatural delay in the passage of a liquid or solid bolus. The esophageal or oropharyngeal phases of swallowing could be when the delay occurs. This exercise discusses oropharyngeal and esophageal dysphagia evaluation and management and emphasises the importance of the interprofessional team in assessing and improving care for patients with dysphagia.
Figure 1. Global Dysphagia Management Market Share (%), by Product Type, 2023
Global Dysphagia Management Market – Driver
Increasing treatments for dysphagia
Increasing treatments and cure related to dysphagia can be considered as the growth factor for global dysphagia management market. For instance, on September 20, 2022, reference article by The Mayo Clinics, U.S. provides accurate and independent information published stating that patient should consume a barium solution, which covers oesophagus and improves its visibility on X-rays. The curvature of oesophagus will then change, and doctor can evaluate the muscular activity. To observe the muscles in throat as patient swallow or to check for obstructions in oesophagus that the liquid barium solution might not be able to detect.
Figure 2. Global Dysphagia Management Market Share (%), by Region, 2023
Global Dysphagia Management Market - Regional Analysis
Among regions, North America is estimated to hold a dominant position in the global dysphagia management market over the forecast period. For instance, on April 25, 2023 an article by American Cancer Society provides accurate and independent information states that the American Dental Association defines "oral cancer" as including cancers of the throat, mouth, tongue, and jaw. According to the American Cancer Society, there will be roughly 11,580 fatal cases and 54,540 new cases of oral or oropharyngeal cancer in the U.S. in 2023. The tongue, tonsils, oropharynx (the throat region behind the mouth), gums, and other regions of the mouth are frequently affected by these tumours. Common warning signs of oral cancer are difficulty in swallowing that is dysphagia or sore thorat.
Global Dysphagia Management Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.
COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.
However, the COVID-19 pandemic had a positive impact on the global dysphagia management market. For instance, according to article published by National Centre for Biotechnology (NCBI) on November 10, 2020 given its potential stimulation as an aerosol-generating procedure (AGP) during the COVID-19 pandemic, national and international institutions recommended against using nasendoscopy. The only patients who received fibre optic endoscopic evaluation of swallowing were those with complex presentations, such as pervasive voice change and dysphagia, which did not improve with compensatory treatments.
Dysphagia Management Market Report Coverage
|Base Year:||2022||Market Size in 2023:||US$ 4.4 Bn|
|Historical Data for:||2017 to 2021||Forecast Period:||2023 to 2030|
|Forecast Period 2023 to 2030 CAGR:||6.2%||2030 Value Projection:||US$ 6.7 Bn|
Eisai Co. Ltd, C.R. Bard Inc. (Becton, Dickinson and Company), Hormel Health Labs, AstraZeneca, Cipla Ltd, Nestle Health Science, Kent Precision Food Group Inc., Bracco Diagnostics Inc., Phagenesis Ltd, Nutricia Advanced Medical Nutrition, Cook medical Inc.
|Restraints & Challenges:||
Global Dysphagia Management Market Segmentation:
The Global Dysphagia Management Market report is segmented into by Product Type, by Indications, by Distributional Channels.
By Product type, the market is segmented into drug, feeding tubes, nutritional solutions. Out of which, the drug segment is expected to hold a dominant position in the global dysphagia management market during the forecast period and this is attributed to the availability of the drug and immediate treatment and results.
By Indications the market is segmented into Oropharangeal Dysphagia, Esophageal Dypshagia. Out of which, the Esophageal Dypshagia segment is expected to hold a dominant position in the global dysphagia management market during the forecast period and this is attributed due to the reduced risk associated with management of dysphagia.
By Distribution channels, the market is segmented into Hospital pharmacies, Retail pharmacies, Drug store, Specialty clinics. Out of which, the hospital pharmacies segment is expected to hold a dominant position in the global dysphagia management market during the forecast period and this is attributed to easy access of supplements and medications.
Among all the segmentations, the product type segment is expected to hold a dominant position in the global dysphagia management market. Out of which drugs create impact on market. For instance, on March 3, 2023, an article published by National Center for Biotechnology Information (NCBI) explains that the potential for Angiotensin-converting-enzyme inhibitors, beta-blockers, and Dipeptidyl peptidase 4 inhibitors to be repurposed as medications in neurological patients with dysphagia to enhance swallowing function and lower the risk of aspiration pneumonia.
Global Dysphagia Management Market Cross Sectional Analysis:
The product type segment is expected to hold a dominant position in the global dysphagia management market. Specialty clinis and hospital pharmacies create a great impact on the dysphagia management market. For instance, On September 20, 2022 The Mayo Clinic,U.S. recently launched the International Dysphagia Diet Standardization Initiative, a global standard for defining diets for people with dysphagia. The framework, known worldwide as International Dysphagia Diet Standardisation Initiative (IDDSI), aligns the Mayo Clinic with international safety standards and provides the highest level of individualized care for people with dysphagia.
Global Dysphagia Management Market: Key Developments
On March 29, 2023 Cook medical, U.S. based company, manufactuerer of medical devices stated according to the Yale School of Medicine, head and neck cancer affected more than 46,000 people last year. Additionally, a 2014 study found that about 1 in 25 adults in the U.S. experience swallowing problems, such as dysphagia in the year.
On March 2, 2023 an article by drugs.com provides accurate and independent information explains study on allergy to a covid vaccine, placebo trails raises questions and results explained that 11 of the 16 patients who received the fake vaccine "developed non-allergic manifestations such as numbness, tingling, dizziness, throat tightness, dysphagia [trouble swallowing], and transient hypertension [high blood pressure] . This will help in development in vaccines to cure te allergies.
Global Dysphagia Management Market: Key Trends
Medications for dysphagia
On December 22, 2022, an article published by Drugs.com provides accurate and independent information states that weekly dupilumab is beneficial in eosinohilic esophagitis. In Part A, the researchers discovered that histologic remission occurred in 60% of patients getting weekly dupilumab and 5% of patients receiving placebo, and in 60% of patients receiving dupilumab every two weeks, weekly, and 6% of patients receiving placebo, respectively. With weekly dupilumab compared to placebo, the mean Dysphagia Symptom Questionnaire (DSQ) scores increased by 12.32 points in Part A and 9.92 points in Part B; no significant difference was observed with dupilumab given every two weeks. This study concluded on weekly subcutaneous dupilumab treatment improved histological findings and alleviated symptoms of eosinophilic esophagitis in both adults and adolescents.
Global Dysphagia Management Market: Restraint
Risk of complications associated with dysphagia
On October 13, 2021 an research article published by European Stroke journal, U.S. states that post-stroke dysphagia (PSD) occurs in more than 50% of acute stroke patients and increases the risk of complications, especially aspiration pneumonia, malnutrition and dehydration, and is associated with poor outcome and mortality. The purpose of this guideline is to assist all members of the multidisciplinary team in the care of PSD patients. These guidelines were developed based on the standard operating procedure of the European Stroke Organization (ESO) and followed the Grading of Recommendations, Assessment, Development and Evaluation (GRADE).
Global Dysphagia Management Market - Key Players
Major players operating in the global dysphagia management market include Eisai Co. Ltd, C.R. Bard Inc. (Becton, Dickinson and Company), Hormel Health Labs, AstraZeneca, Cipla Ltd, Nestle Health Science, Kent Precision Food Group Inc., Bracco Diagnostics Inc., Phagenesis Ltd, Nutricia Advanced Medical Nutrition, Cook medical Inc.
Global Dysphagia Management Market – Definition
Dysphagia is difficulty swallowing - it takes more time and effort to move food or liquid from the mouth to the stomach. Dysphagia can be painful. In some cases, swallowing is impossible. Occasional difficulty swallowing, such as when eat too quickly or don't chew food well enough, is usually nothing to worry about. However, persistent dysphagia can be a serious condition that requires treatment. Dysphagia can occur at any age, but is more common in older adults. The causes of swallowing problems vary, and treatment depends on the cause.
Frequently Asked Questions